Imaging cognitive decline in Multiple Sclerosis: highlighting the hippocampus and thalamus

Completed

Conditions: MS
10012303
Multiple Sclerosis
10003816

Registration Number: NL-OMON33862

Lead Sponsor: Vrije Universiteit Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 140

Inclusion Criteria

- Age 18-65 years
- Clinically definite MS (based on Poser criteria, 1983)
- Need to meet the safety criteria to undergo an MRI examination

Exclusion Criteria

For all participants:;- History of drug abuse
- Psychiatric disorders
- Claustrophobia
- Foreign non MR compatible metal objects in the body
- Foreign metal objects in or close to the head;Additionally for the healthy controls:
- Neurological disorders;Additionally for the patients:
- Other neurological disorders besides MS
- Relapse or steroid treatment in the month prior to the investigation

Study & Design

Study Type: Observational non invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>More insight will be given to the underlying pathobiology of memory impairment<br /><br>(mainly hippocampus and thalamus) in MS. This will increase our understanding<br /><br>of memory dysfunction and will hopefully improve the prediction regarding<br /><br>patients* cognitive profiles in the clinic.<br /><br>The primary study parameters of this study will be:<br /><br>1) Differences between brain activation patterns in healthy controls compared<br /><br>to MS patients during a memory- and attention task. What is the role of<br /><br>functional reorganization.<br /><br>2) The relation between functional measurements (brain activation patterns<br /><br>during a memory- and attention task) and structural measurements (DTI) will be<br /><br>described.<br /><br>3) The relation between structural and functional neuroimaging results will be<br /><br>related to the clinical performance of patients on memory- and attention tasks. </p><br>

Secondary Outcome Measures